$SNY

Sanofi and the pan-Canadian Pharmaceutical Alliance (pCPA) signed a Letter of Intent for Dupixent® covering four new indications in dermatology and respiratory care. The agreement aims to expand patient access through public drug plans. Dupixent is a biologic therapy for conditions like atopic dermatitis and COPD, with over 1.5 million patients treated globally, including 45,000 in Canada. Sanofi is listed on NASDAQ as SNY.

Recursion Pharmaceuticals (RXRX) and Sanofi have collaborated to develop a potential first-in-class oral medicine for inflammatory diseases. Sanofi has optioned the first development candidate, triggering a milestone payment. The candidate is expected to enter phase 1 clinical trials in 2027, with Sanofi funding further development. Recursion's AI-enabled drug discovery platform was used in the development.

A phase 3 trial for ExPEC9V, a vaccine developed by Janssen and Sanofi to prevent invasive E. coli disease (IED) in older adults, was discontinued after showing only 14.6% efficacy. The trial, involving 17,000 participants, found that while the vaccine induced a strong antibody response, it did not prevent IED cases. Investigators suggest the immune response may not have been sufficient for clinical protection. Further analysis is needed to understand the failure.

EU competition chief Teresa Ribera announced a record-fast antitrust settlement with Sanofi, securing benefits for millions receiving flu vaccines. The probe concluded in one year, with Sanofi committing to changes.

Sanofi avoided a potential fine after the EU accepted its offer to stop disparaging CSL Seqirus's Fluad vaccine. The French pharma company proposed measures to address antitrust concerns, including halting negative promotional materials and publishing a clarification statement. The pledge lasts until 2030, according to the EU.

Sanofi-Aventis Korea reduced its National Immunization Program (NIP) flu vaccine supply from 2.25M to 1.75M doses due to production disruptions. The Korea Disease Control and Prevention Agency amended the contract without penalties, allowing Sanofi to divert 500,000 doses to the higher-priced private market. Critics argue this favors Sanofi and may disrupt supply for domestic firms like GCGC Biopharma (006280).

Pennsylvania sued 17 pharma companies and PBMs, including Eli Lilly, Sanofi, and Novo Nordisk, for allegedly colluding to raise insulin prices by over 1,000% since the mid-2000s. The lawsuit claims this harmed 1.3 million diabetics in the state, forcing many to ration insulin. The state seeks restitution and penalties under consumer protection laws.

The Pompe disease market is expected to grow significantly from 2026 to 2036, driven by new therapies and increased awareness. Key therapies in development include MZE001 (Shionogi/Maze Therapeutics), AT845 (Astellas Pharma), and others. The U.S. holds the largest market share, with 66% of diagnosed cases in 2025. Approved treatments include POMBILITI + OPFOLDA (Amicus Therapeutics) and NEXVIAZYME (Sanofi).

Johnson & Johnson's study found 60% of menopausal women don't link vision changes to menopause. UK accepted 44 AI healthcare regulations. GE HealthCare's Photonova Spectra got CE Mark. Bayer plans $2.2B US plant. Sanofi, Regeneron renewed $8B partnership.

A post hoc analysis of the LEVEL UP and HEADS UP trials found no skin lesion flares in patients with moderate to severe atopic dermatitis who switched from dupilumab to upadacitinib (Rinvoq, AbbVie) after 16 weeks. The study, presented at the 2026 Fall Clinical Dermatology Conference, showed infrequent itch flares and suggested upadacitinib's superior efficacy over dupilumab (Dupixent, Regeneron and Sanofi).